Bioforce Nanosciences Holdings, INC

Bioforce Nanoscience has received a preliminary report from Ryder Scott assessing prospective oil and natural gas resources on its Nevada leases, but cautions these are highly speculative and not SEC-compliant reserves.

BioForce NanoScience Holdings, Inc. has announced several key appointments to its leadership and advisory teams, including a new General Counsel, a new Director, and two Advisory Board members, effective May and June 2026.

Bioforce Nanosciences Holdings, Inc. has received approval from the US Bureau of Land Management for federal oil and gas leases covering approximately 19,957 acres in Nye County, Nevada.

Bioforce Nanosciences Holdings, Inc. has acquired federal oil and gas leases covering approximately 19,957 acres in Nye County, Nevada, marking a significant step in its strategic pivot to the energy sector.

BioForce Nanosciences Holdings, Inc. announces a strategic pivot from vitamin supplements to oil and gas, alongside significant changes in its board and executive leadership.

BioForce NanoSciences Holdings has replaced BF Borgers CPA PC with Michael Gillespie & Associates, PLLC as its independent registered public accounting firm, effective May 7, 2024.

BioForce Nanosciences Holdings, Inc. reported its Q2 2026 financial results, highlighting a strategic pivot to the oil and gas industry and a net income of $238,682 for the quarter, contrasting with a net loss in the prior year.

BioForce Nanosciences Holdings, Inc. reported zero revenue for the first quarter of 2026, continuing its transition to a nutritional supplement business while facing ongoing operational challenges and a going concern warning.

BioForce Nanosciences Holdings, Inc. reported a significant net loss for the nine months ended September 30, 2025, with no revenue generated from its nutritional supplement business.

BioForce Nanosciences Holdings, Inc. reported a significant net loss of over $1 million for the first half of 2025, driven by a liability settlement, with no sales revenue generated.

BioForce Nanosciences Holdings reports no sales revenue and a substantial net loss for the quarter ended March 31, 2025, primarily due to a loss on liability settlement.

BioForce Nanosciences Holdings reported no revenue and a net loss for the third quarter of 2024, with ongoing concerns about its ability to continue as a going concern.

BioForce Nanosciences Holdings, Inc. files its 2025 Form 10-K, detailing its transition to nutritional supplements and ongoing financial challenges.

BioForce Nanosciences Holdings reports no revenue for FY 2024, a net loss of $490,437, and expresses substantial doubt about its ability to continue as a going concern.

BioForce Nanosciences Holdings reported no revenue for the fiscal year 2023 and faces substantial doubt about its ability to continue as a going concern.